Antiarrhythmic effect of newly synthesized compound 44Bu on model of aconitine-induced arrhythmia -- compared to lidocaine.

The antiarrhythmic action of the newly developed compound 44Bu (an original compound that was synthesized at our Faculty of Pharmacy) was tested on a model of aconitine-induced arrhythmia and compared with the effect of lidocaine. Both tested substances were administered either as therapeutic or prophylactic agents. 44Bu was highly effective in reducing the occurrence of ventricular fibrillation from 94% to 8% by therapeutic administration, and to 0% by prophylactic administration.

Effect of a new ultrashort betalytic agent on aconitine-induced arrhythmia.

The anti-arrhythmic effect was tested on the model of aconitine-induced arrhythmia. The experiment was performed in vivo with 31 male Wistar laboratory rats. Group A was first administered aconitine and, after the onset of the first sinus rhythm disorders, the 44Bu compound was administered.

[Testing bradycardial effects of a newly synthesized ultra-short beta blocker in laboratory rats].

With the use of normotensive laboratory Wistar strain rats, changes in heart rate induced by three newly synthesized potential ultrashort beta-blockers were tested. The animals were administered the tested substances intravenously in general anesthesia. In all animals, heart rate was measured at predetermined time intervals.